InvestorsHub Logo
Followers 51
Posts 5566
Boards Moderated 3
Alias Born 02/16/2006

Re: None

Wednesday, 02/21/2018 8:07:24 AM

Wednesday, February 21, 2018 8:07:24 AM

Post# of 1345

APHB.... buy out candidate

Shorts covering and going LONG!



Merck to buy Viralytics for $394M

Feb. 21, 2018 5:34 AM ET|About: Merck & Co Inc. (MRK)|By: Yoel Minkoff, SA News Editor



•Already one of the leaders in the hot area of cancer immunotherapy, Merck & Co (NYSE:MRK) has agreed to buy Viralytics (OTCQX:VRACY) for A$502M ($394M) to expand its drug pipeline.

•The deal comes at a time of booming merger and acquisition activity in the biotechnology sector, with $27.5B of transactions agreed in January alone.

•On completion of the transaction, Viralytics will become a subsidiary of Merck.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARMP News